Nanjing University of Chinese Medicine

THURSDAY, Jan. 2, 2025 -- Acupuncture may improve the symptoms of vertigo , tinnitus , ear fullness, and hearing loss in patients with Meniere disease, according to a review published online Dec. 10 in Frontiers in Medicine . Mingjie Tang, from the Nanjing University of Chinese Medicine in China, and colleagues conducted a systematic literature review to evaluate the efficacy of acupuncture treatment for Meniere disease. Based on six studies, the researchers found that treatment of Meniere disease with acupuncture or acupuncture combined with Western medicine was superior to Western medicine alone (control) in terms of efficacy rate (risk ratio, 1.20). Compared with control, acupuncture also reduced the dizziness handicap inventory (mean difference [MD], 6.94), tinnitus handicap inventory (MD, 6.52), stuffy ear visual analog scale (MD, 0.87), and pure tone audiometry score (MD, 6.57). Methodological shortcomings included failure to implement blinding, inappropriate outcome measures, and heterogeneity of clinical interventions, such as selected acupoints, acupuncture sessions, and therapist techniques. "Due to the lack of literature included in this study and methodological weaknesses like randomization, blinding, and clinical heterogeneity, more well-designed long-term follow-up randomized controlled trials are needed to evaluate the efficacy and safety of acupuncture," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off in Nanjing. The theme of the conference is "Let the World Know Jiangsu Traditional Chinese Medicine", according to the organizing committee. Hu Gang, Vice-Chairman of the Jiangsu Provincial Committee of the CPPCC and President of Nanjing University of Chinese Medicine (NJUCM), said in his speech that Chinese medicine is the treasure of ancient Chinese science and the key to the treasure house of Chinese civilization. Jiangsu TCM International Exchange Conference is a powerful measure to link domestic and international markets and resources, and expand the international influence of Jiangsu Traditional Chinese Medicine, which provides new thinking and direction for Chinese medicine to serve the global health cause. Dr. Mary Faria, President & CEO of AOMA Graduate School of Integrative Medicine, said in a video speech that AOMA Graduate School of Integrative Medicine has established a good cooperative partnership with the Foreign Affairs Office of Jiangsu Provincial People's Government, Jiangsu Province Hospital of Chinese Medicine and NJUCM. Through joint efforts to build Jiangsu Overseas Qihuang Talent Training Project, international talents of traditional Chinese medicine have been trained, sincere humanities exchanges have been promoted, the spread of traditional Chinese medicine around the world has been promoted, and deep friendship has been established. It is hoped that all sides will work together to build a platform for international exchanges and cooperation of traditional Chinese medicine and promote deeper exchanges and cooperation between China and the United States in the field of health care. During the opening ceremony, the icon of Jiangsu TCM, the little Shennong, was launched. The world premiere ceremony of the first Chinese and English version of Chinese medicine comic book Little Shennong's Herbal Adventure in China was held; the collection of overseas book donation activities of Little Shennong's Herbal Adventure was broadcast; the awarding ceremony of the Feeling the Pulse of TCM with Z Generation English short video contest for exploring Chinese medicine was held; NJUCM and Mae Fah Luang University, Sunsuria Group of Malaysia and Instituto Piaget held the signing ceremony of TCM "going global" projects. NJUCM, the national "Double First-class" discipline construction university, as the core strength in Jiangsu Provincial Chinese Medicine development, has been in the forefront of facilitating the internationalization of Chinese medicine. Over the last sixty plus years, NJUCM with its affiliated hospitals has trained more than 30,000 international students. NJUCM world-renowned alumni include "The Father of European Chinese Medicine" Giovanni Maciocia, "The Father of Australian Chinese Medicine Legalization" Lin Tzi-Chiang, etc. NJUCM has established two Confucius Institutes for Traditional Chinese Medicine and eight overseas Chinese Medicine Centers. It has been designated as WHO Collaborating Center for Traditional Chinese Medicine for ten terms consecutively. The university has been selected as the first batch of National Base of Chinese Medicine Service Trade, and has established "Belt and Road" Chinese Medicine International Collaboration Base. It has the Chinese medicine clinics that have been the first to get the ISO 9001 certification. NJUCM has contributed greatly in facilitating Chinese medicine into the mainstream medical education system in Europe, and has dedicated to bringing health and well-being to people all over the world by using the advantages of traditional Chinese medicine. SOURCE The Organizing Committee of Jiangsu Traditional Chinese Medicine International Exchange Conference

SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced that initial data from the Phase 3 study of its drug candidate rivoceranib combined with camrelizumab versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma (uHCC) was accepted for a late-breaking proffered paper presentation at the annual Congress of the European Society for Medical Oncology (ESMO) on September 10, 2022 in Paris. Details of the presentation are as follows: Title: Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲ trial Presenter: Shukui Qin, M.D., Ph.D., professor and chief physician of the Cancer Center of Jinling Hospital, Nanjing University of Chinese Medicine Event, Date, Time and Location: ESMO, Saturday, Sept. 10, 8:40 a.m. – 8:50 a.m. CEST, 7.1.C – Cannes Auditorium Session: Proffered Paper Session 1: GI, upper digestive Presentation Number: LBA35 About Rivoceranib Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib is co-developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) in China and by Elevar Therapeutics, Inc. globally (excluding China). It has been studied in more than 6,000 patients worldwide and was well tolerated in clinical trials with a comparable safety pro other TKIs and VEGF inhibitors. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications. Clinical studies are ongoing in multiple solid tumor types including gastric cancer (as a monotherapy and in combination with paclitaxel), hepatocellular carcinoma (HCC) (in combination with camrelizumab), adenoid cystic carcinoma (as monotherapy) and colorectal cancer (in combination with Lonsurf®). Orphan drug designations have been granted in gastric cancer (U.S., EU and South Korea), in adenoid cystic carcinoma (U.S.) and in HCC (U.S.). Elevar holds the global rights (excluding China) and has partnered for the development and marketing of rivoceranib with HLB-LS in South Korea. Rivoceranib, under the name apatinib, is currently approved in China for advanced gastric cancer and in second-line advanced HCC by the Chinese-territory license-holder, JHP, under the brand name Aitan®. About Elevar Therapeutics Elevar Therapeutics, Inc. is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar’s lead proprietary drug candidates include rivoceranib and paclitaxel micellar (Apealea®). Rivoceranib, under the name apatinib in China, was developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. in China and approved in China as a single agent for treatment of gastric cancer in 2014 and second-line advanced HCC in 2020. It has been granted orphan drug designation in the U.S., Europe and South Korea and has been clinically tested in more than 1,000 patients worldwide in numerous cancer indications. Apealea® is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe’s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar has offices in Utah, California, Ireland and South Korea. Additional information is available at . Media Contact Rosemary Ostmann Phone: 201-615-7751 Email: rostmann@rosecomm.com